Good catch. Not sure what it means. Could mean one of two things - either he/they are turning positive, or his short contacts want the price to rise temporarily so they can re-short it. I would prefer the former of course.
I caught that too. On top of that I didn't think it was a well written or compelling article. It gave too much emphasis to convenience rather than kinetics and short and long term health advantages.
My retirement money too, duke. Husband is still with me so far. :) Good to see so many longs still here who have just stopped posting - as have I to a certain extent. Got tired of ignoring idiot shorts and playing whack-a-mole with them.
That is a fabulous ad and what Sanofi should be doing. Old, inactive guys with dorky hats don't cut it for me.
Pkg, as I hope you know I am long and have been since Afrezza was in its post-Shkreli clinicals. I know what I own and have strong faith in Afrezza's efficacy, but what makes you confident a majority or "critical mass" of insurers will step up to the plate? I have argued that the longer term savings achieved by a Afrezza as it reduces the risk of diabetic complications would appeal to insurers. What do you think is the appeal of Afrezza to insurers, and what do you think Sanofi has to do to achieve broad insurance coverage?
Exactly. Anyone who thinks that a new drug, especially one that is a paradigm shift, will breakeven after only a few months show a profit. It's called investment spending.
Couldn't find anything to explain it. Could be nothing but interesting nonetheless.
Who is the person to whom you are referring?
My guess is Mannkind will earn another milestone payment just before the advertising has begun. They will need to produce a ton of product for SNY to fill the pipeline and meet demand and that should trigger the milestone payment. Just a guess. We'll see.